The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease
Open accessAbstract
Abstract Rationale Randomized data comparing triple therapy with dual inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA) therapy in patients with chronic obstructive pulmonary disease (COPD) are limited. Objectives We compared the effects of once-daily triple therapy on lung function and health-related quality of life with twice-daily ICS/LABA therapy in patients with COPD. Methods The FULFIL (Lung Function and Quality of Life Assessment in Chronic Obstructive Pulmonary Disease with Closed Triple Therapy) trial was a randomized, double-blind, double-dummy study comparing 24 weeks of once-daily triple therapy (fluticasone furoate/umeclidinium/vilanterol 100 μg/62.5 μg/25 μg; ELLIPTA inhaler) with twice-daily ICS/LABA therapy (budesonide/formoterol 400 μg/12 μg; Turbuhaler). A patient subgroup remained on blinded treatment for up to 52 weeks. Co–primary endpoints were change from baseline in trough FEV1 and in St. George’s Respiratory Questionnaire (SGRQ) total score at Week 24. Measurements and Main Results In the intent-to-treat population (n = 1,810) at Week 24 for triple therapy (n = 911) and ICS/LABA therapy (n = 899), mean changes from baseline in FEV1 were 142 ml (95% confidence interval [CI], 126 to 158) and −29 ml (95% CI, −46 to −13), respectively, and mean changes from baseline in SGRQ scores were −6.6 units (95% CI, −7.4 to −5.7) and −4.3 units (95% CI, −5.2 to −3.4), respectively. For both endpoints, the between-group differences were statistically significant (P < 0.001). There was a statistically significant reduction in moderate/severe exacerbation rate with triple therapy versus dual ICS/LABA therapy (35% reduction; 95% CI, 14–51; P = 0.002). The safety profile of triple therapy reflected the known profiles of the components. Conclusions These results support the benefits of single-inhaler triple therapy compared with ICS/LABA therapy in patients with advanced COPD. Clinical trial registered with www.clinicaltrials.gov (NCT02345161).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD
Wedzicha, J. A., Banerji, D., Chapman, K. R., Vestbo, J., Roche, N., Ayers, R. T., Thach, C., Fogel, R., Patalano, F., & Vogelmeier, C. F. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516385 · Cited by 844
Vestbo, J., Anderson, J. A., Brook, R. D., Calverley, P. M. A., Celli, B. R., Crim, C., Martinez, F., Yates, J., & Newby, D. E. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30069-1 · Cited by 483
Singh, D., Papi, A., Corradi, M., Pavlišová, I., Montagna, I., Francisco, C., Cohuet, G., Vezzoli, S., Scuri, M., & Vestbo, J. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31354-x · Cited by 425
Dransfield, M. T., Bourbeau, J., Jones, P. W., Hanania, N. A., Mahler, D. A., Vestbo, J., Wachtel, A., Martinez, F. J., Barnhart, F., Sanford, L., et al. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(13)70040-7 · Cited by 345
Tashkin, D. P., Rennard, S. I., Martin, P., Ramachandran, S., Martin, U. J., Silkoff, P. E., & Goldman, M. (2008) · Drugs · doi:10.2165/00003495-200868140-00004 · Cited by 202
De Blaquiere, P., Christensen, D. B., Carter, W. B., & Martin, T. R. (1989) · American Review of Respiratory Disease · doi:10.1164/ajrccm/140.4.910 · Cited by 185
Rennard, S. I., Tashkin, D. P., McElhattan, J., Goldman, M., Ramachandran, S., Martin, U. J., & Silkoff, P. E. (2009) · Drugs · doi:10.2165/00003495-200969050-00004 · Cited by 185
Effect of budesonide/formoterol pMDI on COPD exacerbations: A double-blind, randomized study
Sharafkhaneh, A., Southard, J. G., Goldman, M., Uryniak, T., & Martin, U. J. (2012) · Respiratory Medicine · doi:10.1016/j.rmed.2011.07.020 · Cited by 160
Martínez, F. J., Boscia, J., Feldman, G., Scott-Wilson, C. A., Kilbride, S., Fabbri, L. M., Crim, C. C., & Calverley, P. M. A. (2013) · Respiratory Medicine · doi:10.1016/j.rmed.2012.12.016 · Cited by 125
A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD
Kerwin, E., Scott-Wilson, C. A., Sanford, L., Rennard, S. I., Agustí, A. G. N., Barnes, N. C., & Crim, C. C. (2013) · Respiratory Medicine · doi:10.1016/j.rmed.2012.12.014 · Cited by 101
Siler, T. M., Kerwin, E., Sousa, A. R., Donald, A., Ali, R. Z., & Church, A. (2015) · Respiratory Medicine · doi:10.1016/j.rmed.2015.06.006 · Cited by 74
Treatment Evolution after COPD Diagnosis in the UK Primary Care Setting
Wurst, K., Punekar, Y. S., & Shukla, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105296 · Cited by 64
Goyal, N., Beerahee, M., Kalberg, C. J., Church, A., Kilbride, S., & Mehta, R. S. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0143-4 · Cited by 30
Siederer, S. K., Allen, A., & Yang, S. (2015) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-015-0303-4 · Cited by 11
Cited by
Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD
Lipson, D. A., Barnhart, F., Brealey, N., Brooks, J., Criner, G. J., Day, N. C., Dransfield, M. T., Halpin, D. M. G., Han, M. K., Jones, C. E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713901 · Cited by 1,253
Self-citationTriple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD
Rabe, K. F., Martinez, F. J., Ferguson, G. T., Wang, C., Singh, D., Wedzicha, J. A., Trivedi, R., St. Rose, E., Ballal, S., McLaren, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1916046 · Cited by 690
COPD Guidelines: A Review of the 2018 GOLD Report
Mirza, S., Clay, R. D., Koslow, M. A., & Scanlon, P. D. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.05.026 · Cited by 444
Cardiovascular disease and COPD: dangerous liaisons?
Rabe, K. F., Hurst, J. R., & Suissa, S. (2018) · European Respiratory Review · doi:10.1183/16000617.0057-2018 · Cited by 410
Ferguson, G. T., Rabe, K. F., Martinez, F. J., Fabbri, L. M., Wang, C., Ichinose, M., Bourne, E., Ballal, S., Darken, P., DeAngelis, K., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30327-8 · Cited by 379
Metadata
- Authors
- Lipson, D. A., Barnacle, H., Birk, R., Brealey, N., Locantore, N., Lomas, D. A., Ludwig-Sengpiel, A., Mohindra, R., Tabberer, M., Zhu, C.-Q., & Pascoe, S. J.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-08-15
- Volume
- 196
- Issue
- 4
- Pages
- 438-446
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2604577460
- Cited by
- 327
- References
- 15
- FWCI
- 34.83
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.